Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBined Active Treatment in Type 2 Diabetes with NASH
2019-001987-31Phase 4Terminated
- Sponsor
- German Diabetes Center
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin and semaglutide in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by German Diabetes Center. Primary endpoint: Histological resolution of NASH without progression of fibrosis. Started Jun 2020; status: terminated.
02
Drugs
empagliflozinsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-001987-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001987-31.